Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	hypoxia-inducible factor-proline dioxygenase activity	EGLN3 EGLN2 EGLN1	4.88e-08	4	47	3	GO:0160082
GeneOntologyMolecularFunction	peptidyl-proline 4-dioxygenase activity	EGLN3 EGLN2 EGLN1	6.79e-07	8	47	3	GO:0031545
GeneOntologyMolecularFunction	ferrous iron binding	TET2 EGLN3 EGLN2 EGLN1	7.06e-07	30	47	4	GO:0008198
GeneOntologyMolecularFunction	peptidyl-proline dioxygenase activity	EGLN3 EGLN2 EGLN1	2.65e-06	12	47	3	GO:0031543
GeneOntologyMolecularFunction	L-ascorbic acid binding	EGLN3 EGLN2 EGLN1	1.35e-05	20	47	3	GO:0031418
GeneOntologyMolecularFunction	2-oxoglutarate-dependent dioxygenase activity	TET2 EGLN3 EGLN2 EGLN1	1.64e-05	65	47	4	GO:0016706
GeneOntologyMolecularFunction	vitamin binding	CBLIF HACL1 EGLN3 EGLN2 EGLN1	3.74e-05	161	47	5	GO:0019842
GeneOntologyMolecularFunction	dioxygenase activity	TET2 EGLN3 EGLN2 EGLN1	8.28e-05	98	47	4	GO:0051213
GeneOntologyMolecularFunction	growth factor binding	A2M CHRDL1 FLT1 EPHA5	4.92e-04	156	47	4	GO:0019838
GeneOntologyMolecularFunction	iron ion binding	TET2 EGLN3 EGLN2 EGLN1	6.22e-04	166	47	4	GO:0005506
GeneOntologyMolecularFunction	extracellular matrix binding	ADAMTS15 ZAN BGN	6.77e-04	73	47	3	GO:0050840
GeneOntologyMolecularFunction	voltage-gated monoatomic anion channel activity	GPR89A GPR89B	7.21e-04	17	47	2	GO:0008308
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	TET2 EGLN3 EGLN2 EGLN1	1.11e-03	194	47	4	GO:0016705
GeneOntologyMolecularFunction	monosaccharide binding	EGLN3 EGLN2 EGLN1	1.45e-03	95	47	3	GO:0048029
GeneOntologyMolecularFunction	oxidoreductase activity	TET2 EGLN3 EGLN2 DHRS1 LOXL2 EGLN1 ETFDH	1.96e-03	766	47	7	GO:0016491
GeneOntologyBiologicalProcess	peptidyl-proline hydroxylation to 4-hydroxy-L-proline	EGLN3 EGLN2 EGLN1	1.81e-06	11	47	3	GO:0018401
GeneOntologyBiologicalProcess	peptidyl-proline hydroxylation	EGLN3 EGLN2 EGLN1	3.97e-06	14	47	3	GO:0019511
GeneOntologyBiologicalProcess	4-hydroxyproline metabolic process	EGLN3 EGLN2 EGLN1	4.95e-06	15	47	3	GO:0019471
GeneOntologyBiologicalProcess	protein hydroxylation	EGLN3 EGLN2 EGLN1	3.49e-05	28	47	3	GO:0018126
GeneOntologyBiologicalProcess	response to hypoxia	EGLN3 EGLN2 FLT1 SLC2A1 LOXL2 EGLN1	1.32e-04	348	47	6	GO:0001666
GeneOntologyBiologicalProcess	synapse organization	CHRDL1 KY NPTN ALS2 CHAT BDNF EGLN1 EPHA5	1.42e-04	685	47	8	GO:0050808
GeneOntologyBiologicalProcess	response to decreased oxygen levels	EGLN3 EGLN2 FLT1 SLC2A1 LOXL2 EGLN1	1.69e-04	364	47	6	GO:0036293
GeneOntologyBiologicalProcess	peptidyl-proline modification	EGLN3 EGLN2 EGLN1	2.54e-04	54	47	3	GO:0018208
GeneOntologyBiologicalProcess	positive regulation of long-term neuronal synaptic plasticity	NPTN BDNF	2.76e-04	11	47	2	GO:0048170
MousePheno	abnormal innervation	EGLN3 ALS2 CHAT ALCAM BDNF EPHA5	3.33e-05	193	45	6	MP:0002184
Domain	2OG-FeII_Oxy_3	EGLN3 EGLN2 EGLN1	2.28e-06	11	46	3	PF13640
Domain	P4Hc	EGLN3 EGLN2 EGLN1	7.66e-06	16	46	3	SM00702
Domain	Pro_4_hyd_alph	EGLN3 EGLN2 EGLN1	7.66e-06	16	46	3	IPR006620
Domain	2OG-FeII_Oxy	EGLN3 EGLN2 EGLN1	1.32e-05	19	46	3	PF03171
Domain	FE2OG_OXY	EGLN3 EGLN2 EGLN1	1.80e-05	21	46	3	PS51471
Domain	Oxoglu/Fe-dep_dioxygenase	EGLN3 EGLN2 EGLN1	2.39e-05	23	46	3	IPR005123
Domain	ADAM_spacer1	THSD4 ADAMTS15	1.45e-03	23	46	2	IPR010294
Domain	ADAM_spacer1	THSD4 ADAMTS15	1.45e-03	23	46	2	PF05986
Domain	ACR	ADAMTS15 ADAM7	2.00e-03	27	46	2	SM00608
Domain	ADAM_Cys-rich	ADAMTS15 ADAM7	2.00e-03	27	46	2	IPR006586
Domain	VWFC_1	CHRDL1 ZAN	3.54e-03	36	46	2	PS01208
Domain	VWC	CHRDL1 ZAN	3.94e-03	38	46	2	SM00214
Domain	VWFC_2	CHRDL1 ZAN	3.94e-03	38	46	2	PS50184
Domain	GDS_CDC24_CS	ALS2 VAV2	4.15e-03	39	46	2	IPR001331
Domain	Peptidase_M12B_N	ADAMTS15 ADAM7	4.15e-03	39	46	2	IPR002870
Domain	Pep_M12B_propep	ADAMTS15 ADAM7	4.15e-03	39	46	2	PF01562
Domain	DISINTEGRIN_1	ADAMTS15 ADAM7	4.36e-03	40	46	2	PS00427
Domain	Reprolysin	ADAMTS15 ADAM7	4.36e-03	40	46	2	PF01421
Domain	ADAM_MEPRO	ADAMTS15 ADAM7	4.36e-03	40	46	2	PS50215
Domain	DISINTEGRIN_2	ADAMTS15 ADAM7	4.36e-03	40	46	2	PS50214
Domain	Peptidase_M12B	ADAMTS15 ADAM7	4.36e-03	40	46	2	IPR001590
Domain	Disintegrin_dom	ADAMTS15 ADAM7	4.58e-03	41	46	2	IPR001762
Domain	Kinesin_motor_CS	KIF9 KIF19	4.58e-03	41	46	2	IPR019821
Domain	VWF_dom	CHRDL1 ZAN	4.80e-03	42	46	2	IPR001007
Domain	Kinesin-like_fam	KIF9 KIF19	5.03e-03	43	46	2	IPR027640
Domain	KINESIN_MOTOR_1	KIF9 KIF19	5.26e-03	44	46	2	PS00411
Domain	-	KIF9 KIF19	5.26e-03	44	46	2	3.40.850.10
Domain	Kinesin_motor_dom	KIF9 KIF19	5.26e-03	44	46	2	IPR001752
Domain	Kinesin	KIF9 KIF19	5.26e-03	44	46	2	PF00225
Domain	KINESIN_MOTOR_2	KIF9 KIF19	5.26e-03	44	46	2	PS50067
Domain	KISc	KIF9 KIF19	5.26e-03	44	46	2	SM00129
Pathway	PID_HIF2PATHWAY	EGLN3 EGLN2 FLT1 SLC2A1 EGLN1	2.85e-08	34	38	5	M44
Pathway	WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA	EGLN3 EGLN2 SLC2A1 EGLN1	1.96e-06	34	38	4	M39771
Pathway	PID_HIF1A_PATHWAY	EGLN3 EGLN2 EGLN1	1.70e-05	19	38	3	M180
Pathway	KEGG_RENAL_CELL_CARCINOMA	EGLN3 EGLN2 SLC2A1 EGLN1	3.62e-05	70	38	4	M13266
Pathway	REACTOME_DISEASES_OF_METABOLISM	THSD4 ADAMTS15 CBLIF OPLAH BGN	5.24e-04	250	38	5	M27554
Pathway	WP_MARKERS_OF_KIDNEY_CELL_LINEAGE	EGLN3 EGLN2 EGLN1	5.29e-04	59	38	3	M46460
Pubmed	Adaptation of the Oxygen Sensing System during Lung Development.	EGLN3 EGLN2 SLC2A1 EGLN1	6.11e-10	10	47	4	35242281
Pubmed	Molecular oxygen sensing: implications for visceral surgery.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	22395314
Pubmed	Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	23690557
Pubmed	Systemic hypoxia mimicry enhances axonal regeneration and functional recovery following peripheral nerve injury.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	32814068
Pubmed	The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	36509284
Pubmed	Characterization and comparative analysis of the EGLN gene family.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	11574160
Pubmed	Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	27561929
Pubmed	Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	22262480
Pubmed	Loss of Prolyl-Hydroxylase 1 Protects against Biliary Fibrosis via Attenuated Activation of Hepatic Stellate Cells.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	30248340
Pubmed	Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	21887331
Pubmed	Hematological, hepatic, and retinal phenotypes in mice deficient for prolyl hydroxylase domain proteins in the liver.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	24508125
Pubmed	Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	27502280
Pubmed	Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	27981571
Pubmed	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	22343896
Pubmed	Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	24195777
Pubmed	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	20959442
Pubmed	Mammalian EGLN genes have distinct patterns of mRNA expression and regulation.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	12234095
Pubmed	Role of the intracellular localization of HIF-prolyl hydroxylases.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	19339211
Pubmed	Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	26774962
Pubmed	Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	24037093
Pubmed	C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	11595184
Pubmed	HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	11595178
Pubmed	Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	21877141
Pubmed	Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	31500697
Pubmed	Expression of HIF prolyl hydroxylase isozymes in growth plate chondrocytes: relationship between maturation and apoptotic sensitivity.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	17044072
Pubmed	Improved vascular survival and growth in the mouse model of hindlimb ischemia by a remote signaling mechanism.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	24440788
Pubmed	Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	28418093
Pubmed	Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	22786772
Pubmed	Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	12615973
Pubmed	Opposing regulation and roles for PHD3 in lung dendritic cells and alveolar macrophages.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	28716863
Pubmed	Roles of individual prolyl-4-hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	22615432
Pubmed	Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	33819286
Pubmed	Prolyl hydroxylase domain proteins regulate bone mass through their expression in osteoblasts.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	27614241
Pubmed	Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function.	EGLN3 EGLN2 EGLN1	2.31e-09	3	47	3	20600011
Pubmed	The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	21748337
Pubmed	Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	18056838
Pubmed	A conserved family of prolyl-4-hydroxylases that modify HIF.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	11598268
Pubmed	Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	22955912
Pubmed	Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	17646578
Pubmed	Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	24145445
Pubmed	Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	12163023
Pubmed	Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	12788921
Pubmed	Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	26818499
Pubmed	Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	19338032
Pubmed	Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	16958618
Pubmed	Transmembrane Prolyl 4-Hydroxylase is a Novel Regulator of Calcium Signaling in Astrocytes.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	33298456
Pubmed	Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells.	EGLN3 EGLN2 EGLN1	9.24e-09	4	47	3	12670503
Pubmed	Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury.	EGLN3 EGLN2 SLC2A1 EGLN1	1.40e-08	20	47	4	21270129
Pubmed	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	27565342
Pubmed	DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	20727020
Pubmed	Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	15156561
Pubmed	Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	16155211
Pubmed	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	18176562
Pubmed	Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	18264140
Pubmed	Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	22006925
Pubmed	Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	18040029
Pubmed	Treatment of erythropoietin deficiency in mice with systemically administered siRNA.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	22611156
Pubmed	PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	18347341
Pubmed	TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation.	TET2 EGLN3 EGLN1	2.31e-08	5	47	3	32963106
Pubmed	Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	15247232
Pubmed	Isoform-specific Roles of Prolyl Hydroxylases in the Regulation of Pancreatic β-Cell Function.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	34718519
Pubmed	Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice.	EGLN3 EGLN2 EGLN1	2.31e-08	5	47	3	18332118
Pubmed	Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	26054543
Pubmed	CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	38518771
Pubmed	Reactivation of hepatic EPO synthesis in mice after PHD loss.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	20651146
Pubmed	Determination and comparison of specific activity of the HIF-prolyl hydroxylases.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	15474027
Pubmed	Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	25846796
Pubmed	ATF4 promotes bone angiogenesis by increasing VEGF expression and release in the bone environment.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	23649506
Pubmed	PHD3 Loss Promotes Exercise Capacity and Fat Oxidation in Skeletal Muscle.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	32663458
Pubmed	Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	22014577
Pubmed	Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia.	EGLN3 EGLN2 EGLN1	4.61e-08	6	47	3	15210114
Pubmed	Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.	EGLN3 EGLN2 EGLN1	8.06e-08	7	47	3	27088801
Pubmed	The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability.	EGLN3 EGLN2 EGLN1	8.06e-08	7	47	3	17353276
Pubmed	The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO.	EGLN3 EGLN2 EGLN1	1.29e-07	8	47	3	22464323
Pubmed	Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes.	EGLN3 EGLN2 EGLN1	1.29e-07	8	47	3	27683416
Pubmed	Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation.	EGLN3 EGLN2 EGLN1	1.29e-07	8	47	3	37400498
Pubmed	Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.	EGLN3 EGLN2 EGLN1	1.93e-07	9	47	3	19147576
Pubmed	Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.	EGLN3 EGLN2 EGLN1	1.93e-07	9	47	3	16511565
Pubmed	PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2.	EGLN3 EGLN2 EGLN1	1.93e-07	9	47	3	24828078
Pubmed	Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.	EGLN3 EGLN2 SLC2A1 EGLN1	2.09e-07	38	47	4	20185832
Pubmed	Deletion of hypoxia-inducible factor prolyl 4-hydroxylase 2 in FoxD1-lineage mesenchymal cells leads to congenital truncal alopecia.	EGLN3 EGLN2 SLC2A1 EGLN1	5.45e-07	48	47	4	35247391
Pubmed	The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor α.	EGLN3 SLC2A1 EGLN1	6.55e-07	13	47	3	27325674
Pubmed	The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.	EGLN3 EGLN2 EGLN1	6.55e-07	13	47	3	22286099
Pubmed	The Oxygen Sensor PHD2 Controls Dendritic Spines and Synapses via Modification of Filamin A.	EGLN3 EGLN2 EGLN1	8.33e-07	14	47	3	26972007
Pubmed	Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.	EGLN3 EGLN1	1.79e-06	2	47	2	38400673
Pubmed	Testis-enriched kinesin KIF9 is important for progressive motility in mouse spermatozoa.	KIF9 HYDIN	1.79e-06	2	47	2	32072696
Pubmed	SM-20 is a novel growth factor-responsive gene regulated during skeletal muscle development and differentiation.	EGLN3 EGLN1	1.79e-06	2	47	2	10543731
Pubmed	Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction.	EGLN3 EGLN1	1.79e-06	2	47	2	31356139
Pubmed	Cellular oxygen sensing: Importins and exportins are mediators of intracellular localisation of prolyl-4-hydroxylases PHD1 and PHD2.	EGLN2 EGLN1	1.79e-06	2	47	2	19631610
Pubmed	GPHR-dependent functions of the Golgi apparatus are essential for the formation of lamellar granules and the skin barrier.	GPR89A GPR89B	1.79e-06	2	47	2	22572823
Pubmed	The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.	EGLN3 EGLN1	1.79e-06	2	47	2	19737309
Pubmed	1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.	EGLN2 EGLN1	1.79e-06	2	47	2	28594552
Pubmed	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia.	EGLN2 EGLN1	1.79e-06	2	47	2	25263965
Pubmed	Endothelial prolyl hydroxylase 2 is necessary for angiotensin II-mediated renal fibrosis and injury.	EGLN2 EGLN1	1.79e-06	2	47	2	32715763
Pubmed	Role of prolyl hydroxylase domain proteins in the regulation of insulin secretion.	EGLN3 EGLN2	1.79e-06	2	47	2	26997627
Pubmed	Examining the effects of the histone methyltransferase inhibitor BIX-01294 on histone modifications and gene expression in both a clinical population and mouse models.	CHAT BDNF	1.79e-06	2	47	2	31185023
Pubmed	GPHR is a novel anion channel critical for acidification and functions of the Golgi apparatus.	GPR89A GPR89B	1.79e-06	2	47	2	18794847
Pubmed	Human PRP19 interacts with prolyl-hydroxylase PHD3 and inhibits cell death in hypoxia.	EGLN3 EGLN2	5.36e-06	3	47	2	20599946
Pubmed	Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors.	EGLN3 EGLN2	5.36e-06	3	47	2	18927305
Pubmed	Analysis of HIF-prolyl hydroxylases binding to substrates.	EGLN3 EGLN1	5.36e-06	3	47	2	17069766
Interaction	HIF3A interactions	EGLN3 EGLN2 EGLN1	2.58e-06	12	47	3	int:HIF3A
Interaction	TET3 interactions	TET2 EGLN3 EGLN1	2.04e-05	23	47	3	int:TET3
GeneFamily	Kinesins\|Pleckstrin homology domain containing	KIF9 KIF19	2.13e-03	46	27	2	622
GeneFamily	Immunoglobulin like domain containing	NPTN FLT1 ALCAM	2.90e-03	193	27	3	594
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	ALS2 VAV2	4.34e-03	66	27	2	722
Coexpression	NABA_ECM_REGULATORS	A2M ADAMTS15 KY EGLN3 EGLN2 LOXL2 ADAM7 EGLN1	9.52e-09	238	47	8	M3468
Coexpression	NABA_ECM_REGULATORS	A2M ADAMTS15 KY EGLN3 EGLN2 LOXL2 ADAM7 EGLN1	1.08e-08	242	47	8	MM17062
Coexpression	NABA_MATRISOME	THSD4 A2M ADAMTS15 CHRDL1 KY EGLN3 EGLN2 LOXL2 BDNF ADAM7 EGLN1 BGN	1.48e-07	1008	47	12	MM17056
Coexpression	NABA_MATRISOME	THSD4 A2M ADAMTS15 CHRDL1 KY EGLN3 EGLN2 LOXL2 BDNF ADAM7 EGLN1 BGN	1.79e-07	1026	47	12	M5889
Coexpression	NABA_MATRISOME_ASSOCIATED	A2M ADAMTS15 CHRDL1 KY EGLN3 EGLN2 LOXL2 BDNF ADAM7 EGLN1	5.95e-07	738	47	10	MM17058
Coexpression	NABA_MATRISOME_ASSOCIATED	A2M ADAMTS15 CHRDL1 KY EGLN3 EGLN2 LOXL2 BDNF ADAM7 EGLN1	6.97e-07	751	47	10	M5885
Coexpression	GSE11961_FOLLICULAR_BCELL_VS_GERMINAL_CENTER_BCELL_DAY7_DN	USP7 ADAMTS15 ALS2 CFAP251 ZAN SLC2A1	1.52e-06	200	47	6	M9341
Coexpression	JONES_OVARY_ENDOTHELIAL	A2M FLT1 ITM2A EGLN1 BGN	1.05e-05	162	47	5	M48350
Coexpression	NABA_MATRISOME_POORLY_METASTATIC_MELANOMA_TUMOR_CELL_DERIVED	THSD4 LOXL2 BGN	1.36e-05	26	47	3	M47981
Coexpression	ELVIDGE_HIF1A_TARGETS_DN	EGLN3 SLC2A1 LOXL2 EGLN1	2.16e-05	91	47	4	M2513
Coexpression	MANALO_HYPOXIA_UP	EGLN3 ITM2A LOXL2 EGLN1 BGN	3.27e-05	205	47	5	M259
Coexpression	ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN	EGLN3 SLC2A1 LOXL2 EGLN1	3.66e-05	104	47	4	M6189
Coexpression	NABA_MATRISOME_POORLY_METASTATIC_MELANOMA	THSD4 LOXL2 BGN	4.36e-05	38	47	3	M47982
Coexpression	ELVIDGE_HYPOXIA_BY_DMOG_UP	EGLN3 SLC2A1 LOXL2 EGLN1	9.27e-05	132	47	4	M9197
Coexpression	ISSAEVA_MLL2_TARGETS	A2M ALCAM LOXL2	1.81e-04	61	47	3	M2281
Coexpression	PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN	FLT1 ITM2A LOXL2 BGN	2.04e-04	162	47	4	M1459
CoexpressionAtlas	dev gonad_e13.5_M_InterstitTestis_Sma_k-means-cluster#1_top-relative-expression-ranked_100	ALCAM ITM2A BGN	2.68e-05	27	46	3	gudmap_dev gonad_e13.5_M_InterstitTestis_Sma_k1_100
CoexpressionAtlas	Mesoderm Day 30-reprogram_OSK-L-l-p53KD_vs_Mesoderm Day 30-reprogram_NA-Confounder_removed-fold2.0_adjp0.05	EGLN3 ALCAM ITM2A SLC2A1	4.11e-05	89	46	4	PCBC_ratio_MESO-30_from-OSK-L-l-p53KD_vs_MESO-30_from-ESC_cfr-2X-p05
CoexpressionAtlas	Mesoderm Day 30-method_episomal_vs_Mesoderm Day 30-method_NA-Confounder_removed-fold2.0_adjp0.05	EGLN3 ALCAM ITM2A SLC2A1	4.11e-05	89	46	4	PCBC_ratio_MESO-30_from-episomal_vs_MESO-30_from-ESC_cfr-2X-p05
CoexpressionAtlas	dev gonad_e12.5_M_InterstitTestis_Sma_k-means-cluster#4_top-relative-expression-ranked_200	ALCAM ITM2A LOXL2	1.03e-04	42	46	3	gudmap_dev gonad_e12.5_M_InterstitTestis_Sma_k4_200
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-immature_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	A2M MYDGF FLT1 ITM2A LOXL2 EGLN1	5.51e-08	194	47	6	bf8e78d53802ac758be1c3db833779c26a94e1d5
ToppCell	E12.5-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	FLT1 HAS3 ITM2A BDNF BGN	1.19e-06	177	47	5	5cdf413f82376a95467322b16d10b0d1e7557e2d
ToppCell	18-Airway-RBC\|Airway / Age, Tissue, Lineage and Cell class	USP7 PIP5K1B OSBP2 TTK SLC2A1	1.30e-06	180	47	5	35bf5f35cf346a5b27f5e819b77db34130d70db1
ToppCell	18-Airway-RBC-RBC\|Airway / Age, Tissue, Lineage and Cell class	USP7 PIP5K1B OSBP2 TTK SLC2A1	1.30e-06	180	47	5	3b4b220a3c150426ae55239baff756f1a7f1e1d7
ToppCell	LPS_only-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	EGLN3 FLT1 ALCAM ITM2A LOXL2	1.74e-06	191	47	5	a7b18bcf27c38ad2353c239ecb309c80f3ef3359
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 ITM2A LOXL2 BDNF BGN	1.83e-06	193	47	5	800b0f5705fefcd3608e37801afae8a94474723e
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 ITM2A LOXL2 BDNF BGN	1.92e-06	195	47	5	6e875c83f838241b5fcaf4a3249b1408d74521dc
ToppCell	E12.5-Mesenchymal-mesenchymal_fibroblast-mesenchymal_alveolar_niche_cell\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	FLT1 ALCAM ITM2A BGN EPHA5	1.92e-06	195	47	5	febe746099964b9ea9e75f2efc72c962c01f0421
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M EGLN3 FLT1 ITM2A LOXL2	1.97e-06	196	47	5	5609b2d93172a488b35d854298a3a4e504e17e28
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_capilar-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	THSD4 A2M FLT1 ITM2A SLC2A1	1.97e-06	196	47	5	889c9fed857f64664ca1f47fcec9fecb15ed103c
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_capilar\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	THSD4 A2M FLT1 ITM2A SLC2A1	2.02e-06	197	47	5	e567f91fa398fd306d025dcfe89bd50a60216537
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-A\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M FLT1 ITM2A LOXL2 BGN	2.02e-06	197	47	5	9244f087ba4b60fdc81d54ce91860de715b3e12c
ToppCell	PND14-Mesenchymal-Mesenchymal_myocytic\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 ADAMTS15 LOXL2 BDNF BGN	2.02e-06	197	47	5	8c728cd3c0382c4f3e4b78647b6e1447bb40ace1
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like-A\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M FLT1 ITM2A SLC2A1 BGN	2.07e-06	198	47	5	72e8b9cccb7b0a2ea9d415218fff4fa2f09728f4
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M FLT1 ITM2A SLC2A1 BGN	2.07e-06	198	47	5	e1fa02184ce93c4f8aa5cf04b70949cd4c425ff0
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 EGLN3 LOXL2 BDNF BGN	2.07e-06	198	47	5	b258f672529fb2c03e62e2696d335043c4963280
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_immature\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M FLT1 ITM2A SLC2A1 BGN	2.12e-06	199	47	5	9c40b3ee39860e9d8edafd007daec11abdd95435
ToppCell	Non-neuronal-Postmitotic-Endothelial\|World / Primary Cells by Cluster	A2M FLT1 ITM2A SLC2A1 BGN	2.12e-06	199	47	5	b9763ac9857a60db6f1f104fe1e9ea2266cf931b
ToppCell	Non-neuronal-Postmitotic-Endothelial-Endothelial-24\|World / Primary Cells by Cluster	A2M FLT1 ITM2A SLC2A1 BGN	2.12e-06	199	47	5	0b4edf3e359749827ef978a77b5267ddde732d71
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	A2M FLT1 ITM2A SLC2A1 BGN	2.12e-06	199	47	5	72b34bce8157abe389e95cd3ed8ba578dce0cbf6
ToppCell	Non-neuronal-Postmitotic-Endothelial-Endothelial\|World / Primary Cells by Cluster	A2M FLT1 ITM2A SLC2A1 BGN	2.12e-06	199	47	5	9e01eee126247a0696c71b019f855a8a41a0ede3
ToppCell	Hematolymphoid-Endothelial-NOSTRIN\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	032df80aa5c40991e1c1e80f9d8da106e6aeaee2
ToppCell	Hematolymphoid-Endothelial-NOSTRIN---\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	68fce28690246895fd33354b30960ebcc31aa4cc
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-3m-Neuroepithelial-Proteoglycan-expressing_cell\|3m / Sample Type, Dataset, Time_group, and Cell type.	A2M ALCAM ITM2A LOXL2 BGN	2.18e-06	200	47	5	94ef227b2162ba77af33b8cc8aaa4a7e3bdf79a7
ToppCell	Hematolymphoid-Endothelial-NOSTRIN-\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	376b19ab5a7cd2c85f726d8ba41337d4525863e5
ToppCell	distal-1-Endothelial-Bronchial_Vessel_2\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	A2M EGLN3 FLT1 SLC25A25 ITM2A	2.18e-06	200	47	5	aa8f8a0271c1363981e6ca1b2c1f0a8eb2652602
ToppCell	Hematolymphoid-Endothelial-NOSTRIN--\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	7fa54370221ed61bac0e09e6bcf1f3dff202a846
ToppCell	droplet-Skin-nan-21m-Epithelial-keratinocyte_stem_cell\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHAT ALCAM ITM2A BDNF BGN	2.18e-06	200	47	5	69295705fc614c2687f2b6c8e6aa0c6717841008
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-3m-Neuroepithelial\|3m / Sample Type, Dataset, Time_group, and Cell type.	A2M ALCAM ITM2A LOXL2 BGN	2.18e-06	200	47	5	429028c3112d279b26abf3296e01b1884b4b7fcb
ToppCell	Biopsy_IPF-Mesenchymal-HAS1_High_Fibroblasts\|Biopsy_IPF / Sample group, Lineage and Cell type	ADAMTS15 CHRDL1 SLC12A8 BDNF BGN	2.18e-06	200	47	5	d02e256b5d65a5c982ba5696bc7e077281ca3e24
ToppCell	Hematolymphoid-Endothelial-NOSTRIN----L2-6\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	878bbbe32e3602723aa14ef32877ab2453b8c6e5
ToppCell	Hematolymphoid-Endothelial\|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic	THSD4 FLT1 ITM2A SLC2A1 BGN	2.18e-06	200	47	5	7136936d05ab344a560cf159684c881063b5430d
ToppCell	E16.5-samps-Mesenchymal-Myofibroblast-Smooth_Muscle-like_MyoFibroblast\|E16.5-samps / Age Group, Lineage, Cell class and subclass	ADAMTS15 CHRDL1 EGLN3 ADAM7	1.44e-05	140	47	4	5623a0a68403fc00166b7d13d13e184a718d9bdd
ToppCell	Leuk-UTI-Lymphocyte-T_NK-CD4_CTL\|Leuk-UTI / Disease, Lineage and Cell Type	OSBP2 ITM2A HYDIN KIF19	2.10e-05	154	47	4	170a421fd69dba2929568c72e983ae9cfaf2aabc
ToppCell	facs-Lung-24m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ZAN HYDIN ADAM7 EPHA5	2.56e-05	162	47	4	bf886e22ff2a20353499004b53f25fb9e6574896
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	2.75e-05	165	47	4	3d14f37b8a9c0ddc1130e60a2e08556bad1fb855
ToppCell	Ciliated_cells-B-IPF_04\|World / lung cells shred on cell class, cell subclass, sample id	CFAP251 UROC1 HYDIN KIF19	3.24e-05	172	47	4	187ae91148d293537afc77e10da2b64302322224
ToppCell	URO-Lymphocyte-B-Plasmablast\|URO / Disease, Lineage and Cell Type	NEMP1 EGLN3 CFAP251 TTK	3.24e-05	172	47	4	48888ef50ac784b38aca81da68f8a94ce09c670d
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_prolif\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ADAMTS15 LOXL2 BDNF BGN	3.39e-05	174	47	4	778e0317c0c63fa4efd74114feb760975b819d92
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 SLC12A8 LOXL2 BDNF	3.62e-05	177	47	4	4553ee8cd9c24db6511b09fe49ed11a89e7cde9e
ToppCell	Endothelial-A-Donor_05\|World / lung cells shred on cell class, cell subclass, sample id	A2M FLT1 ITM2A BGN	3.78e-05	179	47	4	138fd6ba6bdbd0ad01c574168addf720b67a0fea
ToppCell	T_cells-GZMK+_CD8+_T_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	A2M ADAMTS15 CFAP251 ITM2A	3.78e-05	179	47	4	798f208014f2229c597934775646ddbbacf94b69
ToppCell	5'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC-Fetal_venous_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M FLT1 ZAN EGLN1	4.03e-05	182	47	4	d0e3663f7d39f22a3ebd7fde56ab3504773598f4
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 LOXL2 BDNF BGN	4.12e-05	183	47	4	b4f29dd3994009bb5eb769d36d95886664e7f87d
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M ZAN HYDIN EPHA5	4.21e-05	184	47	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M ZAN HYDIN EPHA5	4.21e-05	184	47	4	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M EGLN3 SLC25A25 ITM2A	4.21e-05	184	47	4	16ed515fb673a9d6973133afcda0a3fba4a8d9dc
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M ZAN HYDIN EPHA5	4.21e-05	184	47	4	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B ALCAM BGN	4.39e-05	186	47	4	6568358812f0ca4e0161a1a1b29682fbced35c79
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	4.39e-05	186	47	4	db4d9ac89cc1e55062ba888b3410b773340595dd
ToppCell	343B-Endothelial_cells-Endothelial-E-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	A2M PIP5K1B FLT1 ITM2A	4.39e-05	186	47	4	dae6a98963c78bf7518ebab8dc02f173c3b0f7f7
ToppCell	E12.5-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ADAMTS15 ALCAM ITM2A BDNF	4.39e-05	186	47	4	1587667e5084ac43505d027af925ba711e228150
ToppCell	343B-Endothelial_cells-Endothelial-E\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	A2M PIP5K1B FLT1 ITM2A	4.39e-05	186	47	4	080e56113b89138277a2bd2eabddfa6cd1a18b61
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-proliferating_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	A2M NEMP1 FLT1 LOXL2	4.39e-05	186	47	4	a844d4f79e0ad5d6c60a4488ffd8f4f21b7eed04
ToppCell	5'-GW_trimst-1.5-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	4.48e-05	187	47	4	6820bfbe552ea5e62cfe699687b051a17d9fda61
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma\|TCGA-Prostate / Sample_Type by Project: Shred V9	GPR89A SLC12A8 KIF9 VAV2	4.48e-05	187	47	4	fa0452f3382c22c0391b241d06504fda3c6a19f0
ToppCell	Fetal_29-31_weeks-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	THSD4 EGLN3 FLT1 ITM2A	4.48e-05	187	47	4	97b2463fb37e7196dd2f92553acf8e7bc3ec40dd
ToppCell	PCW_07-8.5-Endothelial-Endothelial_mature-endo_capillary_(2)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	EGLN3 FLT1 ITM2A SLC2A1	4.48e-05	187	47	4	106f50ad85a92403037214f0e94702230284837f
ToppCell	TCGA-Prostate-Primary_Tumor\|TCGA-Prostate / Sample_Type by Project: Shred V9	GPR89A SLC12A8 KIF9 VAV2	4.48e-05	187	47	4	3e6a95c912dad5d61e10497ffaafd2b9027cd13a
ToppCell	Endothelial-A-SSc-ILD_02\|World / lung cells shred on cell class, cell subclass, sample id	A2M FLT1 ITM2A BGN	4.48e-05	187	47	4	febe0b99a6a815ce687160a0e7af55228b1d5beb
ToppCell	21-Trachea-Epithelial-Multiciliated_cell\|Trachea / Age, Tissue, Lineage and Cell class	KIF9 CFAP251 HYDIN KIF19	4.58e-05	188	47	4	803bf76a85b3033d2a04b08dd2c03ce9c15529ba
ToppCell	human_hepatoblastoma-Tumor_cells-T5\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	PIP5K1B HYDIN SLC2A1 BDNF	4.58e-05	188	47	4	b070a0667f1ee9b825b267b6c389b7c42fc436f9
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_capilar-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	THSD4 FLT1 ITM2A SLC2A1	4.67e-05	189	47	4	f44ddb6cdbb406b0528a9b0ba3811183ab6d1fc6
ToppCell	LPS_only-Endothelial-Endothelial-Alv_Gen_Intermediate\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	EGLN3 FLT1 ITM2A LOXL2	4.67e-05	189	47	4	e82211b9dc7540e7a183be2cbcfae39fdf503949
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF9 CFAP251 HYDIN KIF19	4.67e-05	189	47	4	b4b93bd10b7e3cc16e54ff73beac230f519c010a
ToppCell	PCW_10-12-Endothelial-Endothelial_mature-endo_bronchial_(8)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PIP5K1B EGLN3 FLT1 ITM2A	4.67e-05	189	47	4	033a2be8bbb7bfb437e6f1657b6ca02070c74aa8
ToppCell	Endothelial-A-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	A2M FLT1 ZAN ITM2A	4.77e-05	190	47	4	6e83fa0eb8cabe0ffb35375f16e6bf3755ec4977
ToppCell	PCW_05-06-Endothelial-Endothelial_cycling-endo_proliferating1_(10)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	A2M EGLN3 FLT1 ITM2A	4.77e-05	190	47	4	9a2244c3973aee7270646bf00db7727edb9decc5
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF9 CFAP251 HYDIN KIF19	4.87e-05	191	47	4	683e5c7e6173644f01e67c98ab7b75d7cb9cce99
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 LOXL2 BDNF BGN	4.87e-05	191	47	4	9431ffd6b758f756609d9057de2023596e22b5d4
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CHRDL1 ITM2A LOXL2 BGN	4.87e-05	191	47	4	4b50fdd310701251e64e16cd2d07ce03dbfd3e3e
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CHRDL1 ITM2A LOXL2 BGN	4.87e-05	191	47	4	75d2197076a9dfc868e8baf95bd4c5e44f438e3e
ToppCell	PCW_07-8.5-Endothelial-Endothelial_immature-endo_immature3_(11)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	EGLN3 FLT1 ITM2A SLC2A1	4.97e-05	192	47	4	7dbe3117a0f58ff2e838963d49f788a59a4351d7
ToppCell	Ciliated-cil-3\|World / Class top	KIF9 CFAP251 HYDIN KIF19	4.97e-05	192	47	4	4989ebb8812b8af1870599acd932849122c05a29
ToppCell	5'-GW_trimst-1.5-LargeIntestine-Mesenchymal-Pericytes\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	4.97e-05	192	47	4	71863f18a82394ed9f8e5ec8a4017215382a8284
ToppCell	multiciliated\|World / shred by cell class for turbinate	KIF9 CFAP251 HYDIN KIF19	4.97e-05	192	47	4	0f89ea0deb651ca11531c51ee94e0233608d22ea
ToppCell	(2)_5-FU-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)\|World / Stress and Cell class	NPTN ITM2A LOXL2 BGN	5.07e-05	193	47	4	f31398dad5321a7bcb27e208bd73630e9756e897
ToppCell	PCW_07-8.5-Endothelial-Endothelial_immature-endo_immature_arterial1_(12)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	PIP5K1B EGLN3 FLT1 ITM2A	5.07e-05	193	47	4	d338a7c0585b69947c37f44aa0381619493e31ea
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THSD4 ADAMTS15 BDNF BGN	5.07e-05	193	47	4	323d1f3f4fbeb93ba857fc135d8aa0b897f98ac5
ToppCell	15-Trachea-Epithelial-Multiciliated_cell\|Trachea / Age, Tissue, Lineage and Cell class	KIF9 CFAP251 HYDIN KIF19	5.07e-05	193	47	4	aa3acc7571405169efb656d214f3a8cbf988362e
ToppCell	ILEUM-inflamed-(8)_Smooth_muscle_cells\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	THSD4 A2M LOXL2 BGN	5.07e-05	193	47	4	084c88f08ce0ecd6c9f4334caed370eb2154f896
ToppCell	5'-GW_trimst-2-SmallIntestine-Endothelial-blood_vessel_EC-cycling_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M EGLN3 FLT1 EGLN1	5.07e-05	193	47	4	dd443b83d328a9069ffe19ac3d74066e922515a5
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Activated_Alv_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	THSD4 EGLN3 ITM2A LOXL2	5.07e-05	193	47	4	a3636c35ed25aabe2f1aba016c9fe125327bbfaf
ToppCell	wk_08-11-Hematologic-Meg-ery-Definitive_erythroblast\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	USP7 PIP5K1B OSBP2 SLC2A1	5.07e-05	193	47	4	be75abfdf5301cf33df8ee9ed92504d44fdf19a6
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ITM2A LOXL2 BDNF BGN	5.07e-05	193	47	4	7386fadc13a437f3b0c99b5d116cd3c5f893529c
ToppCell	facs-Bladder-nan-18m-Epithelial-bladder_mesenchymal_cell_(Car3+)\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THSD4 LOXL2 BDNF BGN	5.17e-05	194	47	4	f4c9fc53ae31d58096906d9305b0b4082512a7e9
ToppCell	PCW_13-14-Endothelial-Endothelial_mature-endo_capillary_(2)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	EGLN3 FLT1 ITM2A SLC2A1	5.17e-05	194	47	4	3c31ac44e8cf4eca3ba7b8bfc05ad3e96a970956
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M ADAMTS15 CHRDL1 VAV2	5.17e-05	194	47	4	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	3'-GW_trimst-2-SmallIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	5.17e-05	194	47	4	b4f4730a53a63118c02a3692a9c52adfd7201598
ToppCell	3'-GW_trimst-1-SmallIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	5.17e-05	194	47	4	7a7406c3b021aeafde423d20290c681c3e8ea0a6
ToppCell	droplet-Bladder-Unstain-18m-Epithelial-bladder_cell\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THSD4 LOXL2 BDNF BGN	5.17e-05	194	47	4	ee6b5fb4e993a4c0dc556091b8fefd56bdc70d8f
ToppCell	PCW_13-14-Endothelial-Endothelial_immature-endo_immature_arterial1_(12)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PIP5K1B EGLN3 FLT1 ITM2A	5.17e-05	194	47	4	32ba2cf9b8726bc3c6e9dc24b54d22ff188bb12b
ToppCell	wk_20-22-Endothelial-Blood_vessel_endothelial-Aerocyte\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	EGLN3 FLT1 ITM2A LOXL2	5.17e-05	194	47	4	54b7126b83f7482227aeaea065f504b65fa34bfe
ToppCell	PCW_05-06-Endothelial-Endothelial_cycling\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	A2M EGLN3 FLT1 ITM2A	5.17e-05	194	47	4	eb279e0d922de921343f0ae032a809f837d915b3
ToppCell	PCW_10-12-Endothelial-Endothelial_immature-endo_immature4_(5)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PIP5K1B EGLN3 FLT1 ITM2A	5.17e-05	194	47	4	53a5e8863d79a052dff0758f389be5ac3883c721
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	5.17e-05	194	47	4	3b9ada901dfe7a5cc4861a883d3268c53b11e5b6
ToppCell	droplet-Bladder-Unstain-18m-Epithelial-bladder_mesenchymal_cell_(Car3+)\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THSD4 LOXL2 BDNF BGN	5.27e-05	195	47	4	841fde528ecb293e07b5e00e499d1e9f0b0dce14
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-Pericytes\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	5.27e-05	195	47	4	815ac5dacd382b11abb32011ed1c0635b0ddc779
ToppCell	Control-Myeloid-Migratory_DC\|Myeloid / Condition, Lineage and Cell class	A2M KCNN1 EGLN3 LOXL2	5.27e-05	195	47	4	9f1ad04abc6a6c5e093ea24b60732871b1fad5a4
ToppCell	3'-GW_trimst-1-SmallIntestine-Mesenchymal-Pericytes\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PIP5K1B BDNF BGN	5.27e-05	195	47	4	9b3fa1d42ec5aa2911f27a99cd8b57714c6bd604
Drug	tyrphostin AG17	CHRDL1 FLT1 SLC2A1 BGN	3.72e-08	17	47	4	CID000126295
Drug	lead sulfide	XRN1 USP7 CBLIF CHRDL1 CHAT FLT1 BDNF BGN	5.56e-08	260	47	8	CID000014819
Drug	homovanillic acid	EGLN3 CHAT LOXL2 BDNF BGN	1.68e-06	97	47	5	CID000001738
Drug	Vitamin C	EGLN3 EGLN2 EGLN1	1.07e-05	21	47	3	DB00126
Drug	C11866	EGLN3 EGLN1	1.25e-05	3	47	2	CID000443459
Drug	N-acetylcysteine	USP7 MYDGF CBLIF PIP5K1B EGLN2 FLT1 SLC25A25 OPLAH	1.43e-05	546	47	8	CID000000581
Drug	Corticosterone	A2M EGLN3 FLT1 SLC2A1 BDNF OPLAH	1.96e-05	272	47	6	ctd:D003345
Drug	SM-11	CHRDL1 EGLN1	2.50e-05	4	47	2	CID000486040
Drug	cyfluthrin	CHAT HYDIN BDNF	2.90e-05	29	47	3	ctd:C052570
Drug	tianeptine	CHAT LOXL2 BDNF	3.22e-05	30	47	3	CID000068870
Drug	4-methylcatechol	CBLIF EGLN3 BDNF	3.56e-05	31	47	3	CID000009958
Drug	3'-dCTP	EGLN3 EGLN2 CHAT EGLN1	3.58e-05	90	47	4	CID000153054
Drug	AC1NDZBW	EGLN3 EGLN2 FLT1 SLC2A1 EGLN1	4.11e-05	187	47	5	CID004634040
Drug	AC1NRA7B	A2M SLC2A1	4.15e-05	5	47	2	CID005287741
Drug	tributyltin	CHAT ITM2A SLC2A1 LOXL2 EGLN1 BGN ETFDH	4.40e-05	465	47	7	ctd:C011559
Drug	Ethynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; HL60; HT_HG-U133A	KCNN1 CBLIF SLC12A8 BDNF BGN	5.26e-05	197	47	5	3008_UP
Drug	Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Up 200; 21uM; MCF7; HT_HG-U133A	A2M KCNN1 CHAT SLC2A1 VAV2	5.52e-05	199	47	5	4159_UP
Drug	Piretanide [55837-27-9]; Down 200; 11uM; PC3; HT_HG-U133A	USP7 EGLN3 SLC12A8 LOXL2 EPHA5	5.52e-05	199	47	5	4490_DN
Drug	Iobenguane sulfate; Up 200; 10.8uM; MCF7; HT_HG-U133A	A2M KCNN1 CBLIF SLC12A8 BGN	5.65e-05	200	47	5	6002_UP
Drug	tesaglitazar	HACL1 EGLN3 ALCAM ADAM7 EGLN1 OPLAH ETFDH	7.12e-05	502	47	7	ctd:C501413
Drug	hydroxylysine	HACL1 LOXL2 EGLN1 ETFDH	7.56e-05	109	47	4	CID000001029
Drug	2d3z	EGLN3 EGLN2 EGLN1	8.32e-05	41	47	3	CID009543495
Drug	AC1MJ0CJ	CHRDL1 CHAT	8.70e-05	7	47	2	CID003083266
Drug	AC1L3VO5	EGLN3 EGLN2 FLT1 EGLN1	9.63e-05	116	47	4	CID000123015
Drug	RI-331	EGLN3 EGLN2 EGLN1	1.25e-04	47	47	3	CID000160754
Drug	hydroxylamine	A2M CHRDL1 PIP5K1B CHAT OPLAH	1.44e-04	244	47	5	CID000000787
Drug	5-HIAA	CHAT LOXL2 BDNF EPHA5	1.45e-04	129	47	4	CID000001826
Drug	bismuth germanate	SLC2A1 BGN	1.49e-04	9	47	2	CID006336999
Drug	J 508	A2M LOXL2	1.49e-04	9	47	2	CID000155219
Drug	1 SRE	EGLN3 EGLN2 EGLN1	1.51e-04	50	47	3	CID005357439
Drug	perfluoro-n-undecanoic acid	A2M CBLIF CHRDL1 EGLN3 ALCAM BDNF	1.70e-04	402	47	6	ctd:C101814
Drug	OH-H	EGLN3 EGLN2 EGLN1	1.80e-04	53	47	3	CID000656932
Disease	coffee consumption measurement, tea consumption measurement	XRN1 TET2 BDNF	4.49e-05	44	46	3	EFO_0006781, EFO_0010091
Disease	Alzheimer's disease (is_implicated_in)	XRN1 A2M CHAT BDNF	5.40e-05	132	46	4	DOID:10652 (is_implicated_in)
Disease	alpha-2-macroglobulin measurement	A2M TET2	6.62e-05	8	46	2	EFO_0020138
Disease	2-hydroxyglutaric acid measurement	ADAMTS15 EGLN3	8.50e-05	9	46	2	EFO_0010446
Disease	hematocrit	CHRDL1 EGLN3 EGLN2 ZAN HYDIN VAV2 BDNF EGLN1	1.52e-04	1011	46	8	EFO_0004348
Disease	TOBACCO ADDICTION, SUSCEPTIBILITY TO (finding)	EGLN2 BDNF	1.55e-04	12	46	2	C1861063
Disease	renal cell carcinoma (is_implicated_in)	EGLN3 EGLN2 EGLN1	1.73e-04	69	46	3	DOID:4450 (is_implicated_in)
Disease	vascular dementia (biomarker_via_orthology)	FLT1 BDNF	2.14e-04	14	46	2	DOID:8725 (biomarker_via_orthology)
Disease	Tremor, Rubral	UROC1 SLC2A1	2.81e-04	16	46	2	C0750940
Disease	Ataxia, Appendicular	UROC1 SLC2A1	2.81e-04	16	46	2	C0750937
Disease	Ataxia, Motor	UROC1 SLC2A1	2.81e-04	16	46	2	C0278161
Disease	Abnormal coordination	UROC1 SLC2A1	2.81e-04	16	46	2	C0520966
Disease	Ataxia, Truncal	UROC1 SLC2A1	2.81e-04	16	46	2	C0427190
Disease	Ataxia, Sensory	UROC1 SLC2A1	2.81e-04	16	46	2	C0240991
Disease	age at menarche	TET2 NEMP1 OSBP2 BDNF EPHA5 ETFDH	3.07e-04	594	46	6	EFO_0004703
Disease	peritonsillar abscess	TET2 SLC12A8	3.58e-04	18	46	2	EFO_0007429
Disease	Visual seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0270824
Disease	Epileptic drop attack	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0270846
Disease	Generalized seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0234533
Disease	Clonic Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0234535
Disease	Vertiginous seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0422855
Disease	Gustatory seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0422854
Disease	Seizures, Somatosensory	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0422850
Disease	Olfactory seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0422853
Disease	Seizures, Auditory	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0422852
Disease	Generalized Absence Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C4505436
Disease	Convulsive Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0751494
Disease	Seizures, Sensory	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0751496
Disease	Jacksonian Seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0022333
Disease	Non-epileptic convulsion	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0751056
Disease	Atonic Absence Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0751123
Disease	Complex partial seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0149958
Disease	Single Seizure	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C0751110
Disease	Epileptic Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C4317109
Disease	Nonepileptic Seizures	CHAT SLC2A1 BDNF	5.31e-04	101	46	3	C3495874
Disease	Tonic Seizures	CHAT SLC2A1 BDNF	5.46e-04	102	46	3	C0270844
Disease	Absence Seizures	CHAT SLC2A1 BDNF	5.46e-04	102	46	3	C4316903
Disease	Convulsions	CHAT SLC2A1 BDNF	5.46e-04	102	46	3	C4048158
Disease	Seizures, Focal	CHAT SLC2A1 BDNF	5.78e-04	104	46	3	C0751495
Disease	Myoclonic Seizures	CHAT SLC2A1 BDNF	5.78e-04	104	46	3	C4317123
Disease	Tonic - clonic seizures	CHAT SLC2A1 BDNF	5.78e-04	104	46	3	C0494475
Disease	Hereditary Paraganglioma-Pheochromocytoma Syndrome	EGLN2 EGLN1	5.89e-04	23	46	2	C1708353
Disease	Hepatic Form of Wilson Disease	A2M LOXL2	6.42e-04	24	46	2	C1527352
Disease	Hepatolenticular Degeneration	A2M LOXL2	6.42e-04	24	46	2	C0019202
Disease	corneal resistance factor	ADAMTS15 TET2 ALCAM LOXL2 VAV2	6.68e-04	451	46	5	EFO_0010067
Disease	Ataxia	UROC1 SLC2A1	6.97e-04	25	46	2	C0004134
Disease	upper respiratory tract disorder	TET2 SLC12A8	8.76e-04	28	46	2	MONDO_0004867
Disease	Papillary Renal Cell Carcinoma	TET2 FLT1 SLC2A1	1.06e-03	128	46	3	C1306837
Disease	Renal Cell Carcinoma	TET2 FLT1 SLC2A1	1.06e-03	128	46	3	C0007134
Disease	Sarcomatoid Renal Cell Carcinoma	TET2 FLT1 SLC2A1	1.06e-03	128	46	3	C1266043
Disease	Chromophobe Renal Cell Carcinoma	TET2 FLT1 SLC2A1	1.06e-03	128	46	3	C1266042
Disease	Collecting Duct Carcinoma of the Kidney	TET2 FLT1 SLC2A1	1.06e-03	128	46	3	C1266044
Disease	Alcoholic Intoxication	CHAT BDNF	1.14e-03	32	46	2	C0001969
Disease	nephroblastoma (is_marker_for)	FLT1 SLC2A1	1.29e-03	34	46	2	DOID:2154 (is_marker_for)
Disease	Mental Retardation, Psychosocial	UROC1 SLC2A1 BDNF	1.34e-03	139	46	3	C0025363
Disease	Profound Mental Retardation	UROC1 SLC2A1 BDNF	1.34e-03	139	46	3	C0020796
Disease	Mental deficiency	UROC1 SLC2A1 BDNF	1.34e-03	139	46	3	C0917816
Disease	central corneal thickness	ADAMTS15 TET2 LOXL2 VAV2	1.36e-03	309	46	4	EFO_0005213

Protein segments in the cluster

Peptide	Gene	Start	Entry
FYETKCNPMGYTKEG	BDNF	181	P23560
EGKMCGQGVYSYASG	ALS2	1106	Q96Q42
LYSHVQGISYPGGMC	ADAM7	296	Q9H2U9
PGGLGTCKETFNMYY	EPHA5	141	P54756
MVACYPGNGTGYVRH	EGLN3	121	Q9H6Z9
AFGVGSKPCPYMQYC	ADAMTS15	451	Q8TE58
MNVSVCGLYTYGKPV	A2M	246	P01023
PNGVAGMAVSYDGCY	CFAP251	891	Q8TBY9
VMTAFGGKGYFVQTP	HACL1	521	Q9UJ83
VYCGLTTGFVPMYVG	SLC2A1	131	P11166
VQCMTVPGYSKGFGY	KY	241	Q8NBH2
IGYGDMVPHTYCGKG	KCNN1	331	Q92952
CGMFGFPGERTYNTK	LOXL2	231	Q9Y4K0
CPMGFGVKRAYYNGI	BGN	321	P21810
TVGFMSFAVCYKYGP	NEMP1	256	O14524
LLPKFYGLYCMQSGG	PIP5K1B	166	O14986
CYGQTGAGKTYTMMG	KIF9	91	Q9HAQ2
DPLTGEMACVYKGGY	OSBP2	886	Q969R2
FAYGPTGCGKTYTML	KIF19	101	Q2TAC6
PSCHGVLGVYGGMIY	ETFDH	456	Q16134
GTCFIYQAGMPPYKQ	HYDIN	4321	Q4G0P3
TCMYNKIPVGSEEGY	CBLIF	181	P27352
DNKGYFCGEETMPVY	CHRDL1	336	Q9BU40
LSGFGAVNCPYTYMS	GPR89A	161	B7ZAQ6
LSGFGAVNCPYTYMS	GPR89B	161	P0CG08
TKAMVACYPGNGTGY	EGLN1	296	Q9GZT9
GLIVGGACIYKYFMP	ITM2A	66	O43736
YFGCVQCISGPLGMY	HAS3	276	O00219
KAMVACYPGNGLGYV	EGLN2	281	Q96KS0
QYMFNVPYGVGKAAC	DHRS1	156	Q96LJ7
YVFGQCVAGAMYITG	SLC12A8	126	A0AV02
MPFTCSVTYYGPSGQ	ALCAM	216	Q13740
KMTQCYFEGGYQETP	OPLAH	661	O14841
GQLSGQPLCMKQYYG	CHAT	261	P28329
GVAAFYKGYVPNMLG	SLC25A25	331	Q6KCM7
MYGQMTAGSYCYIGP	UROC1	201	Q96N76
EGQDATMYCKSVGYP	NPTN	251	Q9Y639
MLGTPYYGCTGEVQD	XRN1	861	Q8IZH2
GCILYYMTYGKTPFQ	TTK	721	P33981
GTFYQGYMCTKCGVG	VAV2	546	P52735
RPGKYEGGGTMFTYK	THSD4	471	Q6ZMP0
RGPGYTQYGVSMHCV	POLR1B	201	Q9H9Y6
QGGPLMVIVEYCKYG	FLT1	901	P17948
SFKSYYGIPCMKGSQ	TET2	56	Q6N021
TGYVGLKNQGATCYM	USP7	211	Q93009
EIPTTYYGKVCGMCG	ZAN	2056	Q9Y493
GPGDKYTCMFTYASQ	MYDGF	56	Q969H8